SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

What molecular mechanisms link perlecan/HSPG2 upregulation to radioresistance acquisition in prostate cancer?

OPEN

The study identifies perlecan/HSPG2 upregulation in radioresistant cells and shows knockdown sensitizes cells, but the mechanistic pathway connecting perlecan to radiation resistance remains unexplained. Understanding this mechanism is critical for developing targeted radiosensitization strategies. Gap type: unexplained_observation Source paper: The extracellular matrix component perlecan/HSPG2 regulates radioresistance in prostate cancer cells. (2024, Front Cell Dev Biol, PMID:39149513)

Priority: 0.80 Domain: cancer-biology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What molecular mechanisms link perlecan/HSPG2 upregulation to radioresistance acquisition in prostate cancer? is a 0.8 priority gap in cancer-biology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What molecular mechanisms link perlecan/HSPG2 upregulation to radioresistance acquisition in prostate cancer? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (4)

HSPG2→Prostate CancerHSPG2→ParkinsonHSPG2→SchizophreniaHSPG2→Myasthenia Gravis

binds (1)

Hsv-1→HSPG2

binds to (2)

APRIL→HSPG2Herpes simplex virus 1→HSPG2

biomarker for (4)

HSPG2→FibrosisHSPG2→AlsHSPG2→DiabetesHSPG2→Ms

co-localizes with (1)

HSPG2→AMYLOID-BETA

co-regulates clearance with (1)

HSPG2→TREM2

component of (2)

HSPG2→SENILE_PLAQUEHSPG2→CEREBRAL_AMYLOID_ANGIOPATHY

core protein of (1)

HSPG2→HEPARAN_SULFATE

expressed in (4)

HSPG2→AlsHSPG2→AlzheimerHSPG2→CancerHSPG2→ALS

inhibits (4)

HSPG2→HypertensionHSPG2→MsHSPG2→TumorHSPG2→Als

interacts with (9)

HSPG2→Alzheimer's diseaseHSPG2→ALSHSPG2→AlzheimerHSPG2→InflammationHSPG2→Cardiovascular
▸ Show 4 more

involved in (2)

HSPG2→extracellular matrixHSPG2→Cell Adhesion-Mediated Signaling

mediates (1)

HSPG2→PRION-LIKE_SPREADING

participates in (1)

HSPG2→oxidative stress response

platform for (1)

HSPG2→CROSS_SEEDING

promotes aggregation of (2)

HSPG2→TAUHSPG2→ALPHA-SYNUCLEIN

regulates (8)

HSPG2→RadioresistanceHSPG2→Prostate CancerHSPG2→ALSHSPG2→AlsHSPG2→Cancer
▸ Show 3 more

targets (2)

h-54b9e0f5→HSPG2h-c35493aa→HSPG2
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps